S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:ICCM

IceCure Medical (ICCM) Stock Price, News & Analysis

$1.19
+0.01 (+0.85%)
(As of 03/27/2024 ET)
Today's Range
$1.17
$1.22
50-Day Range
$1.18
$1.48
52-Week Range
$0.52
$1.57
Volume
99,421 shs
Average Volume
173,579 shs
Market Capitalization
$54.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.95

IceCure Medical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
147.9% Upside
$2.95 Price Target
Short Interest
Healthy
1.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of IceCure Medical in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.31) to ($0.28) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.30 out of 5 stars

Medical Sector

513th out of 939 stocks

Surgical & Medical Instruments Industry

57th out of 96 stocks

ICCM stock logo

About IceCure Medical Stock (NASDAQ:ICCM)

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

ICCM Stock Price History

ICCM Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
IceCure Medical (NASDAQ:ICCM) Price Target Raised to $2.90
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
IceCure's ProSense® Deepens Regulatory Approval in India
See More Headlines
Receive ICCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IceCure Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/22/2023
Today
3/28/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:ICCM
Employees
65
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.95
High Stock Price Target
$3.00
Low Stock Price Target
$2.90
Potential Upside/Downside
+147.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-16,980,000.00
Net Margins
-535.84%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.09 million
Book Value
$0.56 per share

Miscellaneous

Free Float
44,510,000
Market Cap
$54.29 million
Optionable
Not Optionable
Beta
0.75
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Eyal Shamir (Age 63)
    CEO & Director
    Comp: $467.32k
  • Mr. Ronen Tsimerman CPA (Age 55)
    CFO & COO
    Comp: $331.8k
  • Ms. Tlalit Bussi Tel-Tzure (Age 53)
    Vice President of Business Development & Global Marketing
    Comp: $279.34k
  • Ms. Merav Nir Dotan (Age 55)
    Vice President of Human Resources
    Comp: $197.96k
  • Ms. Galit Malik (Age 51)
    Vice President of Operations & Service

ICCM Stock Analysis - Frequently Asked Questions

Should I buy or sell IceCure Medical stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IceCure Medical in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ICCM shares.
View ICCM analyst ratings
or view top-rated stocks.

What is IceCure Medical's stock price target for 2024?

2 Wall Street analysts have issued 1 year price targets for IceCure Medical's stock. Their ICCM share price targets range from $2.90 to $3.00. On average, they expect the company's stock price to reach $2.95 in the next year. This suggests a possible upside of 147.9% from the stock's current price.
View analysts price targets for ICCM
or view top-rated stocks among Wall Street analysts.

How have ICCM shares performed in 2024?

IceCure Medical's stock was trading at $1.07 at the start of the year. Since then, ICCM shares have increased by 11.2% and is now trading at $1.19.
View the best growth stocks for 2024 here
.

Are investors shorting IceCure Medical?

IceCure Medical saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 242,700 shares, a decline of 57.3% from the February 29th total of 568,600 shares. Based on an average daily trading volume, of 550,100 shares, the short-interest ratio is currently 0.4 days. Currently, 1.2% of the company's shares are short sold.
View IceCure Medical's Short Interest
.

When is IceCure Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our ICCM earnings forecast
.

How were IceCure Medical's earnings last quarter?

IceCure Medical Ltd (NASDAQ:ICCM) released its quarterly earnings results on Monday, May, 22nd. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. The firm had revenue of $0.71 million for the quarter, compared to the consensus estimate of $0.95 million. IceCure Medical had a negative net margin of 535.84% and a negative trailing twelve-month return on equity of 77.41%. During the same quarter in the previous year, the company posted ($0.12) earnings per share.

What guidance has IceCure Medical issued on next quarter's earnings?

IceCure Medical updated its FY 2023 earnings guidance on Wednesday, January, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.2 million-$3.2 million, compared to the consensus revenue estimate of $2.9 million.

Who are IceCure Medical's major shareholders?

IceCure Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (0.11%).

How do I buy shares of IceCure Medical?

Shares of ICCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ICCM) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners